Recent evidence has highlighted that an additional 10% of EOC patients exhibit “BRCAness”, which refers to tumours that share molecular features with tumours possessing pathogenic variants of BRCA1/2, such as those identified through HRR-related gene promoter methylation, beyond what genetic testing alone can reveal [51]. This evidence concerns the gene BRCA1 and neoplasm.